Enicepatide (CT-388) Posts ~22.5% Weight Loss in Phase 2 and Heads to ADA 2026: Roche's Signal-Biased GLP-1/GIP Agonist - June 4, 2026 Peptide Research Update
Table of Contents
A New Heavyweight Enters the Obesity Race
The incretin era of obesity medicine keeps raising its own ceiling. Semaglutide brought roughly 15% weight loss, tirzepatide pushed past 20%, and the experimental triple agonist retatrutide reached into the high twenties. In 2026 a new contender has joined that top tier: enicepatide, known by the development codes CT-388 and RO7795068. Developed by Roche and its U.S. subsidiary Genentech, enicepatide is an investigational once-weekly subcutaneous dual GLP-1/GIP receptor agonist that produced up to about 22.5% placebo-adjusted mean weight loss at 48 weeks in its Phase 2 trial - and notably, did so without reaching a plateau. As the American Diabetes Association (ADA) 2026 Scientific Sessions open in New Orleans (June 5-8), enicepatide's late-breaking 48-week data are among the most anticipated readouts of the meeting.
What the Phase 2 CT388-103 Trial Showed
The Phase 2 CT388-103 study enrolled 469 adults living with obesity or overweight who had at least one weight-related comorbidity, and followed them over 48 weeks across multiple doses. At the highest 24 mg dose, enicepatide delivered a placebo-adjusted weight loss of 22.5% using the efficacy estimand and 18.3% using the more conservative treatment-regimen estimand (p<0.001), with a clear dose-response relationship across the dosing arms. The depth of response stood out: at 24 mg, 95.7% of participants lost at least 5% of body weight, 87% lost at least 10%, 47.8% lost at least 20%, and 26.1% lost at least 30%. Crucially, the weight-loss curve had not flattened by week 48, suggesting the full effect of the drug may not yet have been captured within the study window.
Signal-Biased Agonism: The Mechanism That Sets It Apart
Enicepatide is more than another GLP-1/GIP co-agonist - its differentiation lies in how it engages those receptors. The molecule is engineered as a cAMP signal-biased agonist: it activates both the GLP-1 and GIP receptors potently while recruiting minimal to no beta-arrestin at either receptor. Beta-arrestin is the intracellular protein that drives receptor internalization and desensitization - in effect, the mechanism by which cells turn down their own responsiveness to a drug over time. By minimizing that pathway, enicepatide is designed to limit receptor down-regulation and sustain pharmacological activity for longer. This biased-signaling approach is a conceptual departure from earlier incretins and is part of why researchers are watching whether enicepatide can combine deep efficacy with durable response.
Tolerability and Metabolic Benefits
As with the broader incretin class, gastrointestinal effects were the most common adverse events, but in CT388-103 the majority were mild to moderate. Discontinuation due to adverse events occurred in 5.9% of participants on enicepatide versus 1.3% on placebo - a gap to monitor, though within the range seen for high-efficacy agents in this class. The metabolic signal was striking on the glucose side as well: among participants who were prediabetic at baseline, 73% returned to normal blood glucose by week 48 at the 24 mg dose, reinforcing enicepatide's potential across both obesity and type 2 diabetes. A separate Phase 2 study, CT388-104, is specifically evaluating enicepatide in people who are overweight or obese and have type 2 diabetes.
From Carmot to Roche: The Origin Story
Enicepatide traces back to Carmot Therapeutics, the biotech Roche acquired in 2023 to bolster its cardiometabolic pipeline - a deal that, on the strength of these data, is looking increasingly prescient. Roche reported the positive topline Phase 2 results in late January 2026 and quickly signaled it would move enicepatide into Phase 3 development. The late-breaking ADA presentation (abstract 2813-LB, 'CT-388, a cAMP Signal-Biased GLP-1/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight/Obesity: A 48-Week Phase 2 Study,' Lingvay I et al.) is scheduled for Sunday, June 7, with an accompanying e-Theater presentation and a Roche investor event on June 8.
The Combination Play With Petrelintide
Perhaps the most strategically interesting part of Roche's plan is what comes next. The company has said it will initiate a Phase 2 multi-arm trial of enicepatide and petrelintide fixed-dose combinations around mid-2026. Petrelintide is Roche/Zealand's long-acting amylin analog, which posted its own placebo-level tolerability story from the ZUPREME-1 trial. Pairing a high-efficacy GLP-1/GIP agonist with a well-tolerated amylin analog mirrors an emerging industry thesis - combine complementary mechanisms to maximize weight loss while smoothing tolerability. Enicepatide is therefore being positioned simultaneously as a potential best-in-class standalone medicine and as a backbone for Roche's broader cardiometabolic combination strategy.
Why It Matters and What to Watch
Enicepatide's Phase 2 readout matters because it lands at the very top of the incretin efficacy range while introducing a genuinely new pharmacological idea - signal-biased agonism - to a crowded field. The open questions now are the ones that always follow a strong mid-stage result: Will the magnitude hold up in larger, longer Phase 3 trials? How will the tolerability and discontinuation profile compare head-to-head against tirzepatide and the next wave of agents? And can the fixed-dose petrelintide combination push efficacy higher without a tolerability penalty? For readers tracking the obesity pipeline, the ADA 2026 late-breaker is the next data point - and the mid-2026 combination trial launch is the catalyst to watch after that. As always, enicepatide is investigational, not approved anywhere, and available only through clinical trials; nothing here is medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.